Recent Company News

• 05:32 PM ET Aug 28, 2026
  

  FDA approves Mimrylo (rusfertide) as treatment for adults with polycythemia vera (¥5800.0000, 0)

• 03:13 PM ET Aug 28, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 30-Aug

• 08:20 AM ET Aug 27, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:33 AM ET Aug 28, 2026
  

  Novavax's partners have received approvals for the Nuvaxovid formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan ($9.05, 0.00)

• 05:05 PM ET Aug 26, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:55 AM ET Aug 25, 2026
  

  Huadong Medicine receives NMPA approval for phase Ib/II combination trial of HDP-101 (CNY 27.28, 0.00)

• 02:39 AM ET Aug 24, 2026
  

  Japan's MHLW approves use of Takeda's ORZEYFUL for narcolepsy type 1 in adults (¥5797.0000, 0)

• 07:52 PM ET Aug 21, 2026
  

  StreetAccount Sector Summary - Healthcare Weekly Recap